HIGHTIDE-B (02511) plans to offer a discount of approximately 12.31% for a total of up to 99 million placement shares.

date
21:38 31/07/2026
avatar
GMT Eight
Junshengtai Pharmaceutical-B (02511) announced that on July 31, 2026, the Company entered into a placing agreement with the exclusive placing agent. According to the terms and conditions of the placing agreement, the Company agrees to issue placing shares, while the exclusive placing agent agrees to act as the Company's agent to use its best efforts to solicit not less than six independent placees to subscribe for a total of up to 99 million placing shares at a placing price of HKD 2.28 per placing share.
HIGHTIDE-B (02511) announced that on July 31, 2026, the company entered into a placing agreement with the exclusive placing agent. In accordance with the terms and conditions of the placing agreement, the company agrees to issue placing shares, and the exclusive placing agent agrees to act as the company's agent to use its best efforts to procure at least six independent placees to subscribe for a total of up to 99 million placing shares at a placing price of HKD 2.28 per placing share. The placing price of HKD 2.28 per placing share represents a discount of approximately 12.31% to the closing price per share of HKD 2.60 reported on the Stock Exchange on July 31, 2026 (the date of the placing agreement). Assuming all placing shares are issued, the total amount expected to be raised from the placing is approximately HKD 225.7 million, and the anticipated net proceeds from the placing (after deducting commission and expenses related to the placing) is approximately HKD 223 million.